Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 14, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital movements.
- Shares Purchased: 1,100,000 ordinary shares.
- Purchase Price: 1,427.25 pence per share.
- Treasury Shares Held: 294,672,678 shares (representing 4.90% of total voting rights).
- Shares in Issue: 5,725,018,956 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through a buyback program. Following the transaction on May 14, 2007, the company's Treasury shareholding increased to 294,672,678 shares. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares in issue (5,725,018,956) for accurate calculation of ownership percentages under Disclosure and Transparency Rules.
- Confirm the current Treasury share count (294,672,678) and its impact on total voting rights (4.90%).
- Note that this filing does not contain financial results; investors should refer to Form 20-F or quarterly reports for revenue and earnings data.